Veracyte, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 12V.F | 300463.SZ | RDNT | NEO | RVTY | QGEN | |
|---|---|---|---|---|---|---|
| Market cap | 2.77B | 5.55B | 6.32B | 2.22B | 17.79B | 10.50B |
| P/E (TTM) | 28.8 | — | — | — | 70.9 | 25.8 |
| Forward P/E | -67.7 | 10.6 | 97.9 | 54.5 | 26.9 | 19.5 |
| Price/book | 2.2 | 0.9 | 5.8 | 2.8 | 2.5 | 3.1 |
| Dividend yield | — | — | — | — | 0.18% | 0.69% |
| 1-year change | +14.42% | −23.74% | +1.71% | +61.36% | +76.60% | +14.37% |
| Today | −23.45% | +1.32% | +9.67% | +1.90% | −2.48% | +0.89% |
The closest companies by business and industry (Diagnostics & Research). Prices may be delayed up to 15 min.
Latest news
All 12V.F news ›Veracyte (NASDAQ:VCYT) Issues Earnings Results
Posted by Kim Johansen on Nov 4th, 2026 Check Out Our Latest Research Report on VCYT Veracyte, Inc is a diagnostics company that develops genomic tests to help physicians diagnose cancer, assess disease risk and guide treatment decisions.…
Insider Selling: Veracyte (NASDAQ:VCYT) Director Sells $352,500.00 in Stock
Posted by Mitch Edgeman on Oct 31st, 2026 Jens Holstein also recently made the following trade(s): Shares of NASDAQ:VCYT opened at $50.01 on Friday. The stock has a market cap of $4.02 billion, a PE ratio of 34.32 and a beta of 1.95. The…
Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer
The retrospective analysis of the randomized Phase III STAMPEDE trial provides new Level 1B predictive evidence for Decipher in men with clinically very high-risk nonmetastatic prostate cancer. This ... Phase III Trial Shows Veracyte’s…
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE ...
Veracyte: Strong Diagnostic Growth And Improving Margins
Explore why Veracyte is rated a buy: strong test demand, 15% revenue growth, rising margins, and new product expansion. Click for more on VCYT stock. - Veracyte is rated a buy due to strong diagnostic test demand, robust financials, and…
Transcript : Veracyte, Inc., Q2 2026 Earnings Call, Jul 30, 2026
Presentation Operator MessageOperator Good day, and thank you for standing by. Welcome to the Veracyte Second Quarter 2026 Financial Results Webcast, [Operator Instructions]. Please be advised that... Transcript : Veracyte, Inc., Q2 2026…
Veracyte, Inc. acquired Convergent Genomics, Inc for $180 million.
Veracyte, Inc. entered into agreement to acquire Convergent Genomics, Inc for $180 million on September 10, 2026. The acquisition includes $150 million in upfront cash consideration and up to $30... (NasdaqGM:VCYT) entered into agreement…
Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced to... Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026 SOUTH SAN…
Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test
Prosigna is available as a laboratory-developed test through Veracyte’s CLIA-certified laboratory in San Diego. The Veracyte Access Program offers financial assistance or tailored payment plans for ... Veracyte Secures Medicare…
Veracyte Adds Another Stream to Bladder Franchise, UBS Says
Veracyte is adding an adjacent product to its bladder franchise following its acquisition of Convergent Genomics, UBS Securities said in a Monday note. We view this as a strategic move by VCYT to... Biotechnology & Medical Research…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com7
- markets.businessinsider.com4
- themarketsdaily.com4
- defenseworld.net3
- stocktitan.net3
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 26 articles, not a forecast.